mRNA non-vaccine therapeutics field set to reach $2 billion by 2028

Now, pharma companies such as Moderna, Ultragenyx, Omega Therapeutics, and BioNTech are further exploring mRNA therapeutics for cancer and rare genetic diseases. There are five non-vaccine mRNA therapeutics in clinical trial development, all in Phase I/II. Their combined revenue is estimated to be upwards of $2bn by 2028, with Ultragenyx’s OTX-2002 contributing most significantly to sales, generating $1.6bn during 2028, according to analyst consensus forecasts on GlobalData’s Pharma Intelligence Centre.